Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide.
Screened 2026-08-06 · the tape above runs as of 22:26 UTC · 7 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Masimo Corporation holds its Accumulation at $179.95. Consolidating, no directional conviction, held for 18 days.
As held on the ledger · 2026-08-06
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 18 days
Price at the screen
$179.95
Valuation
44.43 trailing · 26.87 forward price to earnings
Values screen
PASS· score 97.5
Beta
1.10
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
5.20%
Below 33%
Interest-bearing debt is just 5.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
1.33%
Below 33%
Cash held in interest-bearing accounts and securities is 1.3% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OVERVALUED: it trades above our $163.75 fair value estimate, moderate competitive moat, 8.50% revenue growth.
Fair value range in USD, drawn from the 2026-08-06 screen. The gold marker is the market price at the same screen. The price runs 9.0% above the base estimate.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Pulse oximeters priced beyond their signals
Picture a nurse trusting a clip on a finger during chaos, only to learn the company behind it wants investors to pay top dollar for steady but unspectacular growth. Masimo clears the ethical screen yet trades at a 26.9 times forward multiple on 8 percent revenue growth and a thin 5 percent profit margin. Fair value sits 9 percent below the current price, leaving no margin of safety despite a moderate moat and solid 25 percent ROE.
We pass because the numbers do not support the premium. Analysts sit on a hold rating with a median target near the present quote, which tells us the market already prices in most of the visible runway. A business this size rarely compounds fast enough to justify stretching the multiple further.
The real risk lies in competition chipping away at that moat while healthcare budgets stay tight. Low margins leave little room for error if growth slows or reimbursement changes hit. Analysis, not advice.
MASI trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-04Accumulation$179.95+0.0%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it none, with a mean price target of $180.
2026-08-05Accumulation$179.95+0.6%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.6% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it none, with a mean price target of $180.
2026-07-18Accumulation$178.82+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it none, with a mean price target of $180.
2026-07-03Accumulation$178.82+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (98). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$178.82Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with near-perfect ethical score (98). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
